Expansion of OEM sales to supplement and pharmaceutical manufacturers, etc.
First written in FY2016-Q3. 12 of 24 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2023.
19 other companies' latest entry also says "Advanced".
- FY2023AdvancedAnnual report
「Revenue from functional products was ¥1,368 million, up 47.8% from the previous fiscal year. Within this, the OEM business was supported by diet foods and health beverages for healthcare companies and private-label products for drugstores.」
Revenue from functional products, including the OEM business, was ¥1,368 million, up 47.8% from the previous fiscal year, supported by diet foods, health beverages and private-label products for drugstores. - FY2023-Q2AdvancedAnnual report
「OEM business revenue was ¥496 million, up 58.7% year on year. Diet foods and health beverages for healthcare companies remained firm, mainly in Japan, while private-label hair-growth products, including those for drugstores, contributed to sales. We propose products combining evidence-based ingredients centered on our proprietary materials and will continue focusing on projects to sell finished OEM products in Japan and overseas.」
OEM business revenue was ¥496 million, up 58.7% year on year, with supplies of private-label hair-growth products and other items contributing to sales. - FY2023-Q1WorsenedAnnual report
「OEM business revenue was ¥196 million, down 14.0% year on year. Diet foods and health beverages for healthcare companies remained firm, mainly in Japan, while private-label hair-growth products, including those for drugstores, contributed to sales.」
Private-label hair-growth products and other items contributed to the OEM business, but revenue fell 14.0% year on year. - FY2022WorsenedAnnual report
「OEM business revenue was ¥625 million, down 15.4% from the previous fiscal year. Diet foods and health beverages for healthcare companies remained firm, mainly in Japan, but orders for pouch jellies and other products for convenience stores were postponed beyond expectations.」
OEM revenue was ¥625 million, down 15.4% from the previous fiscal year, with the postponement of orders for convenience stores also noted for the full year. - FY2022-Q3WorsenedAnnual report
「OEM business revenue was ¥444 million, down 22.4% from the previous fiscal year. Diet foods and health beverages for healthcare companies remained firm, mainly in Japan, but orders for pouch jellies and other products for convenience stores were postponed beyond expectations. Our OEM business proposes products combining evidence-based ingredients centered on our proprietary materials, and projects continue to progress in Japan and overseas.」
The company continued proposing OEM products combining evidence-based ingredients, but revenue fell 22.4% year on year, with orders for convenience stores postponed. - FY2022-Q2AdvancedAnnual report
「OEM business revenue was ¥312 million, up 2.3% from the previous fiscal year. Diet foods and health beverages for healthcare companies, as well as pouch jellies for convenience stores, increased, mainly in Japan. Our OEM business proposes products combining evidence-based ingredients centered on our proprietary materials, and numerous projects are progressing in Japan and overseas.」
The company continued proposing OEM products combining evidence-based ingredients, and increased supplies of diet foods, health beverages and pouch jellies lifted revenue to ¥312 million, up 2.3% from the previous fiscal year. - FY2022-Q1AdvancedAnnual report
「OEM business revenue was ¥228 million, up 80.9% from the previous fiscal year. Diet foods and health beverages for healthcare companies, as well as pouch jellies for convenience stores, increased, mainly in Japan. Our OEM business proposes products combining evidence-based ingredients centered on our proprietary materials, and numerous projects are progressing in Japan and overseas.」
The company continued proposing OEM products combining evidence-based ingredients, and increased supplies of foods and beverages for healthcare companies lifted revenue to ¥228 million, up 80.9% from the previous fiscal year. - FY2021AdvancedAnnual report
「OEM business revenue was ¥739 million, up 33.7% from the previous fiscal year. Diet foods and other products for healthcare companies, as well as pouch jellies for national brands, increased, mainly in Japan.」
Higher supplies of foods for healthcare companies and pouch jellies for national brands lifted OEM business revenue to ¥739 million, up 33.7% from the previous fiscal year. - FY2021-Q3AdvancedAnnual report
「OEM business revenue was ¥573 million, up 51.3% year on year. Diet foods and other products for healthcare companies, as well as pouch jellies for national brands, increased, mainly in Japan.」
OEM business revenue was ¥573 million, up 51.3% year on year, with increased supplies of foods for healthcare companies and pouch jellies for national brands. - FY2021-Q2AdvancedAnnual report
「OEM business revenue was ¥305 million, up 126.8% year on year. Product supplies increased, mainly in Japan, for diet foods and other products for healthcare companies incorporating our functional food ingredients.」
Higher supplies of diet foods and other products for healthcare companies lifted OEM revenue to ¥305 million, up 126.8% year on year. - FY2021-Q1AdvancedAnnual report
「OEM business revenue was ¥126 million, up 54.3% year on year. Product supplies increased for diet foods and other products for healthcare companies incorporating our functional food ingredients.」
Higher supplies of products incorporating functional food ingredients for healthcare companies lifted OEM revenue to ¥126 million, up 54.3% year on year. - FY2020-Q3AdvancedAnnual report
「In the OEM business, product supplies increased for nutrition bars for healthcare companies and beverages for direct-to-consumer companies, incorporating our functional food ingredients.」
Supplies of nutrition bars and beverages incorporating functional food ingredients increased for healthcare companies and direct-to-consumer companies. - FY2020-Q2AdvancedAnnual report
「Domestic sales in the functional ingredients business increased year on year as domestic sales of PharmaGABAⓇ, our flagship product, and the OEM business rose substantially.」
The company stated that higher domestic sales in the OEM business, including PharmaGABA, led to increased revenue in the functional ingredients business. - FY2020-Q1AdvancedAnnual report
「Sales of our OEM products incorporating our proprietary ingredients and other materials have increased, driven by inquiries from distributors, health food manufacturers and others.」
The company stated that inquiries from distributors, health food manufacturers and others regarding its evidence-based OEM business have translated into higher sales. - FY2019ReframedAnnual report
「Rather than merely providing contract manufacturing, we are pursuing the planning and sale of health foods, supplements and other products in Japan and overseas as an OEM (Original Evidence Manufacturer) business, leveraging evidence and other findings developed through the creation of functional ingredients.」
The company has redefined its conventional OEM sales as an "Original Evidence Manufacturer" business leveraging evidence and has organized its operations around planning and sales in Japan and overseas. - FY2019-Q3RestatedAnnual report
「HGP (Hair Growth Peptide), a hair-growth ingredient derived from egg yolk, is seeing increased adoption by distributors, health food manufacturers and others.」
OEM and sales activities through the adoption of the ingredient by distributors, health food manufacturers and others have continued. - FY2019-Q2RestatedAnnual report
「HGP (Hair Growth Peptide), a hair-growth ingredient derived from egg yolk, is seeing increased adoption by distributors, health food manufacturers and others.」
Sales activities through the adoption of the ingredient by distributors, health food manufacturers and others have continued. - FY2018-Q3RestatedAnnual report
「HGP has attracted attention from distributors and health food manufacturers as an ingestible hair-growth ingredient, and the company is focusing on securing OEM orders and pursuing further expansion.」
The company has continued to receive and expand OEM orders for HGP from distributors and health food manufacturers. - FY2018-Q2AdvancedAnnual report
「HGP has attracted attention from distributors and health food manufacturers as an ingestible hair-growth ingredient, and the company is focusing on securing OEM orders and pursuing further expansion.」
In addition to its conventional OEM sales policy, the company specifically described receiving OEM orders for HGP from distributors and health food manufacturers. - FY2018-Q1RestatedAnnual report
「For OEM product sales, we are actively developing sales to supplement manufacturers, pharmaceutical manufacturers and distributors.」
OEM sales to supplement manufacturers, pharmaceutical manufacturers, distributors and other businesses have continued. - FY2017-Q3RestatedAnnual report
「For OEM product sales, we are actively developing sales to supplement manufacturers, pharmaceutical manufacturers and distributors, and selling functional foods with GABA and other ingredients that carry a Foods with Function Claims designation.」
OEM sales to supplement manufacturers, pharmaceutical manufacturers and distributors, as well as sales of functional foods containing GABA, have continued. - FY2017-Q2RestatedAnnual report
「For OEM product sales, we are actively developing sales to supplement manufacturers, pharmaceutical manufacturers and distributors, and selling functional foods with GABA and other ingredients that carry a Foods with Function Claims designation.」
OEM sales to supplement manufacturers, pharmaceutical manufacturers and distributors, as well as sales of functional foods containing GABA, have continued. - FY2017-Q1RestatedAnnual report
「For OEM product sales, we are actively developing sales to supplement manufacturers, pharmaceutical manufacturers and distributors, and selling functional foods with GABA and other ingredients that carry a Foods with Function Claims designation.」
OEM sales to supplement manufacturers, pharmaceutical manufacturers and distributors have continued. - FY2016-Q3First statedAnnual report
「For OEM product sales, we are actively developing sales to supplement manufacturers and pharmaceutical manufacturers. We have also continued to actively develop sales to distributors and other businesses.」
Sales initiatives to expand OEM product customers to supplement and pharmaceutical manufacturers, distributors and other businesses.